ENGN Share Price Performance
US$3.94
-3.81 (-49.16%)
Price US$3.94
Share PriceUS$3.94
ENGN Community Narratives
There are no narratives available yet.
Recent ENGN News & Updates
No updates
enGene Holdings Inc. Key Details
Last Reported Earnings
Apr 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.56
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 10.4%
enGene Holdings Inc. Competitors
About ENGN
- Founded
- n/a
- Employees
- 57
- CEO
- WebsiteView website
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Canadian Market Performance
- 7 Days: -0.1%
- 3 Months: 8.8%
- 1 Year: 21.9%
- Year to Date: 10.4%
Over the last 7 days, the market has dropped 1.3%, driven by a decline of 2.1% in the Financials sector. In the last year, the market is actually up 19%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading